114 related articles for article (PubMed ID: 36646585)
1. The Impact of Estrogen Receptor Expression on Mutational Status in the Evolution of Non-Small Cell Lung Cancer.
Tani Y; Kaneda H; Koh Y; Tamiya A; Isa S; Kubo A; Ogawa K; Matsumoto Y; Sawa K; Yoshimoto N; Mitsuoka S; Kawaguchi T
Clin Lung Cancer; 2023 Mar; 24(2):165-174. PubMed ID: 36646585
[TBL] [Abstract][Full Text] [Related]
2. Impact of somatic mutations on prognosis in resected non-small-cell lung cancer: The Japan Molecular Epidemiology for lung cancer study.
Tamiya A; Koh Y; Isa SI; Kubo A; Ando M; Saka H; Yoshimoto N; Takeo S; Adachi H; Tagawa T; Kawashima O; Yamashita M; Kataoka K; Takenoyama M; Takeuchi Y; Watanabe K; Matsumura A; Kawaguchi T
Cancer Med; 2020 Apr; 9(7):2343-2351. PubMed ID: 32022477
[TBL] [Abstract][Full Text] [Related]
3. Correlation between epidermal growth factor receptor mutations and expression of female hormone receptors in East-Asian lung adenocarcinomas.
Toh CK; Ahmad B; Soong R; Chuah KL; Tan SH; Hee SW; Leong SS; Tan EH; Lim WT
J Thorac Oncol; 2010 Jan; 5(1):17-22. PubMed ID: 19875972
[TBL] [Abstract][Full Text] [Related]
4. Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC).
Labbé C; Cabanero M; Korpanty GJ; Tomasini P; Doherty MK; Mascaux C; Jao K; Pitcher B; Wang R; Pintilie M; Leighl NB; Feld R; Liu G; Bradbury PA; Kamel-Reid S; Tsao MS; Shepherd FA
Lung Cancer; 2017 Sep; 111():23-29. PubMed ID: 28838393
[TBL] [Abstract][Full Text] [Related]
5. The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer.
Jao K; Tomasini P; Kamel-Reid S; Korpanty GJ; Mascaux C; Sakashita S; Labbé C; Leighl NB; Liu G; Feld R; Bradbury PA; Hwang DM; Pintilie M; Tsao MS; Shepherd FA
Lung Cancer; 2018 Sep; 123():22-29. PubMed ID: 30089591
[TBL] [Abstract][Full Text] [Related]
6. The prognostic value of TP53 and its correlation with EGFR mutation in advanced non-small cell lung cancer, an analysis based on cBioPortal data base.
Jiao XD; Qin BD; You P; Cai J; Zang YS
Lung Cancer; 2018 Sep; 123():70-75. PubMed ID: 30089598
[TBL] [Abstract][Full Text] [Related]
7. Predictive and Prognostic Potential of TP53 in Patients With Advanced Non-Small-Cell Lung Cancer Treated With EGFR-TKI: Analysis of a Phase III Randomized Clinical Trial (CTONG 0901).
Li XM; Li WF; Lin JT; Yan HH; Tu HY; Chen HJ; Wang BC; Wang Z; Zhou Q; Zhang XC; Su J; Chen RL; Wu YL; Yang JJ
Clin Lung Cancer; 2021 Mar; 22(2):100-109.e3. PubMed ID: 33317922
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.
Qin K; Hou H; Liang Y; Zhang X
BMC Cancer; 2020 Apr; 20(1):328. PubMed ID: 32299384
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of mutant p53, Ki-67, and TTF-1 and their correlation with EGFR mutation in patients with non-small cell lung cancer.
Zhu WY; Hu XF; Fang KX; Kong QQ; Cui R; Li HF; He JY; Zhang YK; Le HB
Histol Histopathol; 2019 Nov; 34(11):1269-1278. PubMed ID: 31062864
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological features and EGFR gene mutation status in elderly patients with resected non-small-cell lung cancer.
Nishii T; Yokose T; Miyagi Y; Daigo Y; Ito H; Isaka T; Imai K; Murakami S; Kondo T; Saito H; Oshita F; Yamada K; Matsukuma S; Tsuboi M; Nakayama H; Masuda M
BMC Cancer; 2014 Aug; 14():610. PubMed ID: 25152277
[TBL] [Abstract][Full Text] [Related]
11. EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort.
Varella-Garcia M; Mitsudomi T; Yatabe Y; Kosaka T; Nakajima E; Xavier AC; Skokan M; Zeng C; Franklin WA; Bunn PA; Hirsch FR
J Thorac Oncol; 2009 Mar; 4(3):318-25. PubMed ID: 19247083
[TBL] [Abstract][Full Text] [Related]
12. Prospective Analysis of Oncogenic Driver Mutations and Environmental Factors: Japan Molecular Epidemiology for Lung Cancer Study.
Kawaguchi T; Koh Y; Ando M; Ito N; Takeo S; Adachi H; Tagawa T; Kakegawa S; Yamashita M; Kataoka K; Ichinose Y; Takeuchi Y; Serizawa M; Tamiya A; Shimizu S; Yoshimoto N; Kubo A; Isa S; Saka H; Matsumura A
J Clin Oncol; 2016 Jul; 34(19):2247-57. PubMed ID: 27161973
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor mutation is associated with longer local control after definitive chemoradiotherapy in patients with stage III nonsquamous non-small-cell lung cancer.
Yagishita S; Horinouchi H; Katsui Taniyama T; Nakamichi S; Kitazono S; Mizugaki H; Kanda S; Fujiwara Y; Nokihara H; Yamamoto N; Sumi M; Shiraishi K; Kohno T; Furuta K; Tsuta K; Tamura T
Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):140-8. PubMed ID: 25442336
[TBL] [Abstract][Full Text] [Related]
14. Positive EGFR mutation status is a risk of recurrence in pN0-1 lung adenocarcinoma when combined with pathological stage and histological subtype: A retrospective multi-center analysis.
Ito M; Miyata Y; Tsutani Y; Ito H; Nakayama H; Imai K; Ikeda N; Okada M
Lung Cancer; 2020 Mar; 141():107-113. PubMed ID: 32035371
[TBL] [Abstract][Full Text] [Related]
15. Outcome of Patients With Resected Early-Stage Non-small Cell Lung Cancer and EGFR Mutations: Results From the IFCT Biomarkers France Study.
Mordant P; Brosseau S; Milleron B; Santelmo N; Fraboulet-Moreau S; Besse B; Langlais A; Gossot D; Thomas PA; Pujol JL; Ricordel C; Madelaine J; Lamy R; Audigier-Valette C; Missy P; Blons H; Barlesi F; Westeel V;
Clin Lung Cancer; 2023 Jan; 24(1):1-10. PubMed ID: 36180314
[TBL] [Abstract][Full Text] [Related]
16. EGFR mutations are associated with favorable intracranial response and progression-free survival following brain irradiation in non-small cell lung cancer patients with brain metastases.
Lee HL; Chung TS; Ting LL; Tsai JT; Chen SW; Chiou JF; Leung HW; Liu HE
Radiat Oncol; 2012 Oct; 7():181. PubMed ID: 23110940
[TBL] [Abstract][Full Text] [Related]
17. Relationship between epidermal growth factor receptor gene mutations and clinicopathological features in patients with non-small cell lung cancer in western Turkey.
Unal OU; Oztop I; Calibasi G; Baskin Y; Koca D; Demir N; Akman T; Ellidokuz H; Yilmaz AU
Asian Pac J Cancer Prev; 2013; 14(6):3705-9. PubMed ID: 23886169
[TBL] [Abstract][Full Text] [Related]
18. Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients.
Inoue A; Yoshida K; Morita S; Imamura F; Seto T; Okamoto I; Nakagawa K; Yamamoto N; Muto S; Fukuoka M
Jpn J Clin Oncol; 2016 May; 46(5):462-7. PubMed ID: 26977054
[TBL] [Abstract][Full Text] [Related]
19. EGFR mutations and HER2/3 protein expression and clinical outcome in Chinese advanced non-small cell lung cancer patients treated with gefitinib.
Xu JM; Han Y; Duan HQ; Gao EM; Zhang Y; Liu XQ; Zhang JS; Toschi L; Galetta D; Azzariti A; Paradiso A
J Cancer Res Clin Oncol; 2009 Jun; 135(6):771-82. PubMed ID: 19020901
[TBL] [Abstract][Full Text] [Related]
20. Non-small cell lung carcinomas with CTNNB1 (beta-catenin) mutations: A clinicopathological study of 26 cases.
Thomas de Montpréville V; Lacroix L; Rouleau E; Mamodaly M; Leclerc J; Tutuianu L; Planchard D; Boulate D; Mercier O; Besse B; Fadel É; Ghigna MR
Ann Diagn Pathol; 2020 Jun; 46():151522. PubMed ID: 32442860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
